Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22853116 | 1.00 | FFAR4 (0.45) | FFAR4MEN1KMT2AMAPK1P2RX7 | |
| SCHEMBL30294670 | 0.91 | P2RX7 (0.44) | FFAR4MEN1KMT2AP2RX7CYP3A4 | |
| SCHEMBL22853358 | 0.91 | P2RX7 (0.44) | FFAR4MEN1KMT2AP2RX7CYP3A4 | |
| SCHEMBL22853085 | 0.81 | AKR1C2 (0.46) | FFAR4P2RX7DHODHAKR1C2AKR1C1 | |
| SCHEMBL30294438 | 0.81 | AKR1C2 (0.46) | FFAR4P2RX7DHODHAKR1C2AKR1C1 | |
| SCHEMBL22852776 | 0.81 | KMT2A (0.50) | MEN1KMT2AMAPK1GFERSMN1; SMN2 | |
| SCHEMBL30294601 | 0.81 | KMT2A (0.50) | MEN1KMT2AMAPK1GFERSMN1; SMN2 | |
| SCHEMBL31697321 | 0.80 | FFAR4 (0.48) | FFAR4CYP3A4KCNH2CACNA1CSCN5A | |
| SCHEMBL22208911 | 0.80 | FFAR4 (0.48) | FFAR4CYP3A4KCNH2CACNA1CSCN5A | |
| SCHEMBL22853163 | 0.79 | P2RX7 (0.42) | MEN1KMT2AP2RX7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | FFAR4 3101/4885MEN1 1826/4885KMT2A 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.